As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Taro Pharmaceutical Industries Ltd - Common / Ordinary Stock (TARO).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$3,266 | 0 | |
| 2025 Q3 | 76 | $3,266 | $42.97 | 1 | |
| 2025 Q2 | 76 | $3,266 | $42.97 | 1 | |
| 2025 Q1 | 76 | $3,266 | $42.97 | 1 | |
| 2024 Q4 | 76 | $3,266 | $42.97 | 1 | |
| 2024 Q3 | 76 | $3,266 | -$29,225,778 | $42.97 | 1 |
| 2024 Q2 | 679,768 | $29,229,044 | -$169,213,087 | $42.97 | 15 |
| 2024 Q1 | 4,693,568 | $198,727,915 | -$6,621,701 | $42.34 | 91 |
| 2023 Q4 | 4,847,251 | $202,517,474 | -$1,668,587 | $41.78 | 86 |
| 2023 Q3 | 4,902,124 | $184,861,191 | +$2,884,219 | $37.71 | 81 |
| 2023 Q2 | 4,729,203 | $179,344,414 | +$27,646,290 | $37.93 | 69 |
| 2023 Q1 | 4,145,227 | $100,778,784 | -$1,451,319 | $24.32 | 59 |
| 2022 Q4 | 4,188,416 | $121,604,644 | -$4,699,170 | $29.04 | 57 |
| 2022 Q3 | 4,342,234 | $130,110,654 | -$386,724 | $29.98 | 60 |
| 2022 Q2 | 4,317,596 | $156,142,037 | -$6,612,632 | $36.16 | 67 |
| 2022 Q1 | 4,544,730 | $196,664,803 | -$3,291,866 | $43.26 | 60 |
| 2021 Q4 | 4,617,110 | $231,252,560 | -$728,549 | $50.11 | 67 |
| 2021 Q3 | 4,612,590 | $293,536,765 | -$10,084,462 | $63.63 | 69 |
| 2021 Q2 | 4,762,570 | $342,744,798 | -$12,756,764 | $71.96 | 74 |
| 2021 Q1 | 4,838,699 | $357,276,629 | -$13,743,434 | $73.75 | 78 |
| 2020 Q4 | 5,033,036 | $369,026,991 | +$21,009,210 | $73.42 | 82 |
| 2020 Q3 | 4,785,339 | $261,849,079 | +$1,579,256 | $54.85 | 76 |
| 2020 Q2 | 4,750,136 | $315,258,687 | +$9,005,099 | $66.49 | 82 |
| 2020 Q1 | 4,623,216 | $282,956,291 | +$6,672,928 | $61.20 | 87 |
| 2019 Q4 | 4,398,834 | $384,835,517 | +$18,180,444 | $87.93 | 93 |
| 2019 Q3 | 4,219,809 | $317,150,000 | +$7,262,561 | $75.45 | 98 |
| 2019 Q2 | 4,118,405 | $349,658,000 | +$602,151 | $85.42 | 102 |
| 2019 Q1 | 4,088,094 | $439,285,092 | +$16,260,139 | $108.09 | 100 |
| 2018 Q4 | 3,946,262 | $331,737,862 | -$37,981,297 | $84.64 | 90 |
| 2018 Q3 | 4,305,124 | $420,064,163 | -$5,294,391 | $98.30 | 110 |
| 2018 Q2 | 4,325,034 | $494,663,424 | -$20,440,820 | $115.69 | 104 |
| 2018 Q1 | 4,533,287 | $443,718,714 | -$47,206,367 | $98.74 | 107 |
| 2017 Q4 | 5,012,010 | $520,847,483 | -$77,687,637 | $104.71 | 124 |
| 2017 Q3 | 5,618,347 | $632,591,592 | -$40,700,235 | $112.69 | 132 |
| 2017 Q2 | 5,975,811 | $669,888,688 | -$21,024,204 | $112.06 | 138 |
| 2017 Q1 | 6,166,054 | $721,765,315 | -$34,043,357 | $116.62 | 135 |
| 2016 Q4 | 6,957,180 | $730,968,495 | -$55,425,010 | $105.27 | 150 |
| 2016 Q3 | 7,395,972 | $816,342,886 | +$44,137,736 | $110.51 | 157 |
| 2016 Q2 | 6,989,161 | $1,017,603,574 | +$186,505,841 | $145.60 | 155 |
| 2016 Q1 | 5,748,677 | $822,360,133 | -$7,538,053 | $143.25 | 163 |
| 2015 Q4 | 5,795,856 | $895,711,999 | +$92,174,518 | $154.55 | 150 |
| 2015 Q3 | 5,107,341 | $703,276,473 | +$22,087,208 | $142.89 | 119 |
| 2015 Q2 | 4,753,774 | $682,746,190 | -$35,964,917 | $143.69 | 104 |
| 2015 Q1 | 5,006,460 | $707,137,476 | -$24,433,157 | $141.03 | 95 |
| 2014 Q4 | 5,331,435 | $790,769,463 | -$26,042,922 | $148.19 | 89 |
| 2014 Q3 | 4,555,914 | $700,980,187 | -$27,123,831 | $153.86 | 80 |
| 2014 Q2 | 4,735,261 | $664,047,024 | +$98,382,238 | $140.24 | 72 |
| 2014 Q1 | 4,044,832 | $448,913,260 | -$14,091,211 | $111.00 | 65 |